NAD+ IV Therapy: Clinical Protocols and Research Evidence

NAD+ IV therapy is the intravenous infusion of pharmaceutical-grade NAD+ solution directly into the bloodstream, bypassing the gastrointestinal degradation and first-pass metabolism that limits the oral route. Oral NAD+ is hydrolyzed by intestinal NADases (CD38, CD73) before systemic absorption; intravenous delivery delivers the intact molecule directly to plasma, producing NAD+ and metabolite elevations orders of magnitude above what oral dosing achieves.

The clinical context for IV NAD+ spans three documented application areas in the published literature: (1) pharmacokinetic characterization in healthy subjects, (2) neurochemical and addiction treatment protocols, and (3) longevity/anti-aging clinical settings. IV NAD+ is not FDA-approved for any indication. It is administered in compounding-pharmacy and wellness-clinic settings by licensed practitioners, or in structured clinical research protocols.

The first human pharmacokinetic characterization of IV NAD+ was published by Grant et al. (2019, Frontiers in Aging Neuroscience). In healthy males, 750 mg NAD+ was infused over 6 hours at approximately 2 mg/min. Plasma NAD+ and its metabolites (NMN, AMP, NAM) rose substantially throughout the infusion and were detectable in urine post-infusion, establishing the first human IV NAD+ PK profile.^[9] No adverse events were documented at this infusion rate.

For clinical endpoint data in a disease context, the most robust evidence is from addiction treatment. Blum et al. (2022, Current Psychiatry Research Review) reported a 50-case series in which IV NAD+ (combined with enkephalinase inhibition) produced statistically significant reductions in craving (p=1.06×10⁻⁹), anxiety (p=5.49×10⁻⁷), and depression (p=1.76×10⁻⁴) in treatment-resistant substance use disorder patients. In a 40-patient subset, 100% of urine samples tested negative for illicit substances midway through treatment.^[11]

Historical data: O'Hollaren's 1961 case series (reviewed in Braidy et al. 2020) documented 104+ cases using 500–1000 mg IV NAD+ daily for 4 days followed by maintenance dosing, reporting removal of cravings and withdrawal symptoms without the typical agony of withdrawal.^[12]

As of 2026, large controlled IV NAD+ trials have not been published. The evidence base consists of PK pilot studies, case series, and observational clinic reports. The 2025 Nature Metabolism systematic review concluded that blood NAD+ elevation is consistently achievable but clinical-endpoint translation requires larger, longer RCTs.^[19]

The pharmacological difference is magnitude and speed of NAD+ elevation. Oral NAD+ itself is largely hydrolyzed in the gut; oral precursors NMN and NR are absorbed more intact via dedicated transporters and produce blood NAD+ increases of roughly 2-fold over baseline with daily dosing.^[4][16] IV NAD+ bypasses GI degradation entirely and produces plasma NAD+ elevations that are substantially higher — the Grant et al. pilot study measured sustained plasma NAD+ elevation throughout a 6-hour 750 mg infusion.^[9]

A 2026 real-world retrospective comparison (Reyna et al., Frontiers in Aging) found that IV NAD+ (500 mg) caused moderate-to-severe gastrointestinal symptoms, elevated heart rate, and chest pressure requiring a mean infusion time of 97 minutes. IV NR (500 mg) caused only mild tingling and required only 37 minutes, with all symptoms resolving post-infusion.^[10] This comparison is the first head-to-head real-world tolerability data for clinicians planning IV NAD+ protocols.

In practical terms: IV NR offers faster, better-tolerated IV delivery of a NAD+ precursor; IV NAD+ achieves direct plasma NAD+ elevation but requires slower rates and greater clinical monitoring. Oral NMN and NR are the most accessible form of NAD+ repletion with substantial RCT evidence, though the magnitude of elevation is substantially lower than IV.

The addiction treatment application has the longest published history of any IV NAD+ clinical use. O'Hollaren's 1961 series (reviewed in Braidy et al. 2020, Antioxidants) documented more than 104 cases using 500–1000 mg IV NAD+ daily for 4 days with maintenance dosing, reporting craving removal and withdrawal symptom reduction in opiate and alcohol dependent patients.^[12]

The Blum 2022 publication formalized this in 50 treatment-resistant cases: statistically significant reductions in craving (p=1.06×10⁻⁹), anxiety (p=5.49×10⁻⁷), and depression (p=1.76×10⁻⁴), and urinalysis negativity in a 40-patient subset.^[11] The mechanistic hypothesis is NAD+-dependent restoration of dopamine pathway homeostasis and neurochemical repair.

No large RCT of IV NAD+ for addiction has been published as of 2026. Braidy et al. 2020 explicitly calls for rigorous RCTs with appropriate controls before IV NAD+ can be considered evidence-based addiction treatment.^[12]

The documented outcomes in the published IV NAD+ literature are:

• Plasma NAD+ and metabolite elevation during and after infusion (Grant et al. 2019, PK study, n=6)^[9]
• Significant reduction in craving, anxiety, and depression scores in substance use disorder (Blum et al. 2022, n=50)^[11]
• Withdrawal symptom reduction and craving removal in historical addiction case series (O'Hollaren 1961, reviewed 2020, n>104)^[12]

Clinical outcomes frequently cited in wellness practice (cognitive clarity, energy, mood improvement outside of addiction contexts) appear in observational clinic reports but have not been confirmed in published controlled trials. The 2025 Vinten et al. systematic review concluded that clinical benefit evidence is promising but limited — the field needs larger controlled trials with tissue-level endpoints.^[19]